TJM Labs raises $75M Series B as pharmacy AI moves from pilots to production
What's the deal? TJM Labs has raised a $75 million Series B led by ElephantDealroom has a profile for this one. Try Dealroom →, with participation from Arthur VenturesDealroom has a profile for this one. Try Dealroom → and UpdataDealroom has a profile for this one. Try Dealroom →. The startup said it has now raised $100 million across three rounds in roughly six months and is live in more than 450 pharmacies.
What does it do? TJM Labs builds AI agents that automate operational pharmacy work — prescription intake, data entry, refills, prior authorization support, and patient communication — across the systems teams already use. It says its agents process more than 500,000 pharmacy tasks daily.
What's the endgame? The company is consolidating a fragmented market into a single platform. It has completed two acquisitions, EncoreRx and PharmesolDealroom has a profile for this one. Try Dealroom →, adding automation and voice capabilities. Founder and chief executive Jonathan Adly, a pharmacist for 15 years, said the goal is to automate "the real operational work that slows pharmacy teams down."
Why it stands out: At $75 million, the round sits in the top 8% of all US Series B deals on record, per our funding database — an outsized raise for a vertical AI vendor. The company had been reported as a $10 million Series A business as recently as January 2026, pointing to fast capital accumulation.
What could go wrong? Pharmacies are heavily regulated, making automation hard to deploy and demanding pharmacist oversight. TJM Labs pairs pharmacists with engineers on deployments to keep agents working within real workflows rather than replacing clinical judgment.
The signal: The raise reflects a hotter niche in healthcare AI: back-office automation that can replace technician labor, not just assist clinicians. It lands within a cluster of large AI healthcare deals — including OpenAI's Torch acquisition and Hippocratic AI's purchase of Grove AI — and suggests buyers are moving from experiments to operational deployment. As Elephant general partner Jeremiah Daly put it, the category is "moving from experimentation to infrastructure."
Read more: EIN Presswire
Image credit: ell brown
